이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Genmab 관리

관리 기준 확인 4/4

Genmab's CEO는 Jan G.J. de Winkel, Jun2010 에 임명되었습니다 의 임기는 14.08 년입니다. 총 연간 보상은 DKK 44.30M, 20.8% 로 구성됩니다. 20.8% 급여 및 79.2% 보너스(회사 주식 및 옵션 포함). 는 $ 151.90M 가치에 해당하는 회사 주식의 0.96% 직접 소유합니다. 151.90M. 경영진과 이사회의 평균 재임 기간은 각각 7 년과 7.3 년입니다.

주요 정보

Jan G.J. de Winkel

최고 경영자

DKK 44.3m

총 보상

CEO 급여 비율	20.8%
CEO 임기	14.1yrs
CEO 소유권	1.0%
경영진 평균 재임 기간	7yrs
이사회 평균 재임 기간	7.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jan G.J. de Winkel 의 보수는 Genmab 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	DKK 44m	DKK 9m	DKK 4b
Sep 30 2023	n/a	n/a	DKK 4b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	DKK 42m	DKK 9m	DKK 5b
Sep 30 2022	n/a	n/a	DKK 6b
Jun 30 2022	n/a	n/a	DKK 4b
Mar 31 2022	n/a	n/a	DKK 2b
Dec 31 2021	DKK 38m	DKK 8m	DKK 3b
Sep 30 2021	n/a	n/a	DKK 3b
Jun 30 2021	n/a	n/a	DKK 3b
Mar 31 2021	n/a	n/a	DKK 6b
Dec 31 2020	DKK 37m	DKK 7m	DKK 5b
Sep 30 2020	n/a	n/a	DKK 6b
Jun 30 2020	n/a	n/a	DKK 6b
Mar 31 2020	n/a	n/a	DKK 2b
Dec 31 2019	DKK 35m	DKK 7m	DKK 2b
Sep 30 2019	n/a	n/a	DKK 2b
Jun 30 2019	n/a	n/a	DKK 1b
Mar 31 2019	n/a	n/a	DKK 1b
Dec 31 2018	DKK 28m	DKK 7m	DKK 1b
Sep 30 2018	n/a	n/a	DKK 1b
Jun 30 2018	n/a	n/a	DKK 1b
Mar 31 2018	n/a	n/a	DKK 1b
Dec 31 2017	DKK 27m	DKK 7m	DKK 1b

보상 대 시장: Jan G.J. 의 총 보상 ($USD 6.38M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 13.50M ).

보상과 수익: Jan G.J. 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jan G.J. de Winkel (63 yo)

14.1yrs

테뉴어

DKK 44,300,000

보상

Dr. Jan G.J. van de Winkel, Ph.D. is Independent Director of HOOKIPA Pharma Inc. from 2023 and serves as Chairman of the Board since 2024. Dr. Winkel served as a Member of Advisory board at Thuja Capital M...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jan G.J. de Winkel	Co-Founder	14.1yrs	DKK 44.30m	0.96% DKK 151.4m
Anthony Pagano	Executive VP & CFO	4.3yrs	DKK 19.60m	0.011% DKK 1.7m
Anthony Mancini	Executive VP & COO	4.3yrs	DKK 21.80m	0.0045% DKK 719.6k
Birgitte Stephensen	Executive VP & Chief Legal Officer	14.5yrs	DKK 10.10m	데이터 없음
Christopher Cozic	Executive VP & Chief People Officer	6.7yrs	DKK 13.20m	데이터 없음
Martine van Vugt	Executive VP & Chief Strategy Officer	10.5yrs	DKK 8.90m	데이터 없음
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	no data	DKK 800.00k	0.00061% DKK 96.7k
Judith Klimovsky	Executive VP & Chief Development Officer	7.4yrs	DKK 21.70m	0.014% DKK 2.2m
Tahamtan Ahmadi	Executive VP	3.3yrs	DKK 19.80m	0.0049% DKK 770.3k
Mijke Zachariasse	Senior Director	no data	DKK 1.10m	0.00083% DKK 131.6k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	DKK 800.00k	0.00013% DKK 20.6k
Andrew Carlsen	Senior Director	no data	데이터 없음	데이터 없음

7.0yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: GMAB 의 관리팀은 노련하고 경험 (평균 재직 기간 7.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	2.5yrs	DKK 800.00k	0.00061% DKK 96.7k
Mijke Zachariasse	Senior Director	5.3yrs	DKK 1.10m	0.00083% DKK 131.6k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	2.5yrs	DKK 800.00k	0.00013% DKK 20.6k
Anders Pedersen	Non-Independent Director	20.7yrs	DKK 1.70m	0.011% DKK 1.8m
Elizabeth O'Farrell	Independent Director	2.3yrs	DKK 1.90m	데이터 없음
Deirdre Connelly	Independent Chairman of the Board	7.3yrs	DKK 2.80m	0.0091% DKK 1.4m
Rolf Hoffmann	Independent Director	7.3yrs	DKK 1.50m	0.0053% DKK 840.0k
Pernille Erenbjerg	Independent Deputy Chairman	9.5yrs	DKK 2.10m	0.0076% DKK 1.2m
Paolo Paoletti	Independent Director	9.5yrs	DKK 1.50m	0.0033% DKK 521.5k

7.3yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: GMAB 의 이사회는 경험(평균 재직 기간 7.3 년)으로 간주됩니다.

Genmab 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Genmab A/S Announces Executive Changes

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Recent updates

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Genmab: A Complicated Tale

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab Acquires A Missing Piece For Its Pipeline

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab: Recent Updates Support The Growth Narrative

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab reports Q3 worldwide sales of $2.05B for Darzalex

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab improves FY 2022 guidance

Genmab reports Q2 worldwide net sales of DARZALEX $1.99B

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab: A Royalty Powerhouse With A Strong Pipeline

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab: Looking For Growth At A Reasonable Price

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab: A Biotech Company On The Rise

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab: Ready For More Growth In 2022

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

U.S. Food and Drug Administration Grants Approval to TIVDAK

Seagen Inc. and Genmab A/S Announce FDA Accelerated Approval for TIVDAK™ (Tisotumab Vedotin-Tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab A/S Announces the Lancet Published the Results of FIH Trial

Genmab: Monoclonal Antibody Experts, Low Risk Business Model

Genmab A/S Improves Revenue Guidance for the Full Year of Fiscal 2021

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간